MAPT and Alzheimer disease: Worse motor function, measured using an informant-based questionnaire, was seen in those participants that were AD–/LB+ or AD+/LB– compared with those that were AD–/LB– but, when examining the independent effects of LB, Aβ and tau (in the same model) on motor function, none of the pathologies was significant at this preclinical disease stage (Fig. 2e,j).